31 August 2025

Starpharma annual report and full year financial results

Melbourne, Australia: Starpharma Holdings Ltd (ASX:SPL; OTCQX:SPHRY) today released its annual report and financial results for the year ended 30 June 2013.

Financial Results

  • Net cash burn for the year $9.0M
  • Cash position at end of the year $33.8M
  • Reported loss $5.2M

Operational Highlights

VivaGel®

  • Phase 2 clinical trial completed for prevention of recurrent BV
  • Phase 3 BV treatment clinical trials completed
  • VivaGel® active ingredient shows potential as novel treatment for viral conjunctivitis

Drug Delivery

  • Dendrimer-enhanced version of docetaxel superior across multiple cancer types
  • Dendrimer-enhanced version of docetaxel demonstrates targeted tumour delivery
  • Signing of agreement with AstraZeneca for cancer drug candidates
  • Dendrimer formulation improves anticancer efficacy in lung metastasis model
  • New patents strengthen and expand drug delivery platform

Agrochemicals

  • New agrochemical partnership with Makhteshim Agan
  • New formulations demonstrate further improvement in crop protection

Corporate

  • Receipt of $5.4M R&D tax incentive payment
  • Starpharma named “Company of the Year” in Janssen 2012 Industry Excellence Awards

Commenting on the results, Starpharma CEO Dr. Jackie Fairley said: “The 2013 financial year has been a period of important progress across the three focus areas of our business: VivaGel®, drug delivery, and agrochemicals.  The company has closed the year in a strong financial position and with a number of important clinical and business milestones anticipated in the coming months.” 

Net cash outflows from operating and investing activities for the year were $10.0 million (2012: $9.9 million), with cash reserves at 30 June 2013 of $33.8 million (2012: $42.8 million).  The net loss after tax was $5.2 million (2012: $13.7 million), with the significant reduction due to additional R&D tax incentives recognised in the year.

During the year Starpharma reported positive Phase 2 trial results for VivaGel® for prevention of recurrent bacterial vaginosis (R-BV) supporting its progression into Phase 3, in parallel with advancement of activities for a symptomatic relief product, and the VivaGel® coated condom.  The Company also reported key advances in its dendrimer-docetaxel development in preparation for human trials later this year, as well as new partnerships with AstraZeneca for oncology and in agrochemicals with Makhteshim Agan.

 

Download ASX Announcement: Annual report and full year financial results ( pdf file, 1MB)

This contains certain forward-looking statements.